Levostar Biotech Completes Pre-A Financing to Expand CGT-focused GMP Manufacturing and Safety Testing Platforms

As the new year begins, everything is renewed.Suzhou Levostar Biotechnology Co., Ltd.(hereinafter referred to as“LevoStar Bio”) completed its second round of financing within one year. This round of financing was led byMPCiExclusive investment; the funds will be used to expand and upgrade the GMP manufacturing and safety testing and evaluation platform for cell and gene therapy products.

Levorotatory Star Bio was established in March 2022 and received angel-round investment from JF Capital and Bohe Angel Fund. The entire team has been deeply engaged in the field of drug quality testing and manufacturing for over a decade. Since its inception, the company has been committed to serving the cell and gene therapy (CGT) industry, which is in a phase of explosive growth, with a particular focus on providing support and services to accelerate pipeline development for numerous emerging CGT enterprises. Levorotatory Star has developed a comprehensive set of cost-effective and rigorous solutions tailored to the various stages of CGT companies’ development, ranging from R&D and preclinical phases to clinical trials.

Dr. Wu Xin, Founder and CEO of Levostar“Thank you to MPCi for its recognition and support of Levostar, which also reflects the shared optimism of both MPCi and Levostar regarding the prospects of the cell and gene therapy sector. Cell therapy, gene therapy, and nucleic acid-based therapeutics represented by mRNA drugs have together opened up a third front in humanity’s fight against disease. Although the past year has been marked by a challenging environment, the field of cell and gene therapy has still achieved remarkable global accomplishments. We hope that new investments and development will provide additional ammunition and safeguards for this campaign.”

Sun Linghao, Managing Director of MPCistated: “We remain bullish on the long-term development of cell and nucleic acid therapies in China, and have invested in multiple promising companies across various segments of the industry chain. The Levostar team has been deeply engaged in the industry for many years, possessing extensive experience in the research and development and manufacturing of mRNA therapeutics and other fields. With the rapid growth of the industry, we look forward to partnering with the company over the long term to build a premium brand in the field of contract research and manufacturing services (CRAMS) for cell and nucleic acid therapeutics.”

MPCi, founded in 2008, is a leading venture capital firm in the industry with a long-term focus on early-stage and early-growth investments. It specializes in investing in new technologies, hard tech, industrial digitalization, healthcare, frontier technologies, and new consumption. To date, it has cumulatively invested in over 700 companies, including XPeng Motors, Li Auto, XGIMI Technology, Ronbay Technology, Hithium Energy Storage, PingCAP, Beisen, SiEngine, Taimei Medical Technology, The Beast, Zihai Guo, Simple Love, and MegaRobots.